This post was originally published on this site
HubSpot (NYSE:HUBS) 12% HIGHER; reported Q4 EPS of $1.11, $0.34 better than the analyst estimate of $0.83. Revenue for the quarter came in at $469.7 million versus the consensus estimate of $446.25M. HubSpot sees Q1 2023 EPS of $0.82-$0.84, versus the consensus of $0.59. HubSpot sees Q1 2023 revenue of $473-475M, versus the consensus of $469.51M. HubSpot sees FY2023 EPS of $4.24-$4.32, versus the consensus of $2.85. HubSpot sees FY2023 revenue of $2.05-2.06 billion, versus the consensus of $2.05B.
Otter Tail Corp (NASDAQ:OTTR) 7% HIGHER; will replace UFP Industries in the S&P SmallCap 600
IVERIC bio, Inc. (NASDAQ:ISEE) 6% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the companys New Drug Application (NDA) for avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). The NDA has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of August 19, 2023. The company also announced that, at this time, the FDA has not identified any potential review issues and the FDA is not currently planning to hold an Advisory Committee meeting for ACP.
DoorDash Inc (NYSE:DASH) 6% HIGHER; reported Q4 EPS of ($1.65), $0.98 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $1.82B versus the consensus estimate of $1.77B. Currently expect Q1 Marketplace GOV to be in a range of $15.1B to $15.5B, with Q1 Adjusted EBITDA expected to be in a range of $120M to $170M. Currently expect 2023 Marketplace GOV to be in a range of $60.0B to $63.0B, with Adjusted EBITDA expected to be in a range of $500M to $800M.
DraftKings (NASDAQ:DKNG) 6% HIGHER; reported Q4 EPS of ($0.53), $0.08 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $855M versus the consensus estimate of $798.23M. DraftKings raises FY2023 revenue to $2.85-3.05B, versus the consensus of $2.95B.
Moderna (NASDAQ:MRNA) 6% LOWER; announced interim results from its pivotal Phase 3 safety and immunogenicity trial of mRNA-1010 (P301), an mRNA-based seasonal influenza (flu) vaccine candidate, in adults. The Phase 3 randomized trial was designed to evaluate the safety and immunogenicity of mRNA-1010 in adults 18 years and older in the Southern Hemisphere. mRNA-1010 encodes for hemagglutinin (HA) glycoproteins of the four influenza strains recommended by the World Health Organization (WHO) to prevent influenza, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages.
UFP Industries Inc (NASDAQ:UFPI) 3% LOWER; will replace LHC Group Inc. (NASDAQ:LHCG) in the S&P MidCap 400
